focus -WSS

focus

author：focus 2025-09-27 23:51:53 - browse：1269

Medicare and money photo illustration. — Adobe

Medical technology lobby AdvaMed is fed up with the Centers for Medicare and Medicaid Services. In a letter sent to the agency and shared with STAT, the group urged CMS to act on finalizing a pathway that would make reimbursement for breakthrough devices easier.

CMS has been working on implementing the pathway since 2021. A CMS spokesperson told STAT the agency is working “expeditiously” to finalize it. Scott Whitaker, CEO of AdvaMed, said the device industry is tired of waiting.

“I myself have begun to wonder if they’re really serious about doing this, or if they’re just saying they’re serious about doing it for political reasons or otherwise,” Whitaker told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Experts study whether long Covid risk adds up with each reinfection

WSS

Crowdfunding for unproven stem cell procedures spreads misinformation

Beware reading your test results before your doctor does

Crowdfunding for unproven stem cell procedures spreads misinformation

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Experts study whether long Covid risk adds up with each reinfection

EpiPen alternative approval delay highlights citizen petition issue

focus

focus

knowledge

At least 13 dead in Texas as scorching temps continue

CommonSpirit Health keeps growing, even as it loses money

Psychedelics group wrestles with new pharma identity

Why are Kaiser Permanente staff considering a strike?

Apple is now the first public company to be valued at $3 trillion

Drug cartel violence flares in western Mexico after vigilante leader's killing

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why are Kaiser Permanente staff considering a strike?

New air purifier tech could be key to improving indoor air quality

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

explore

Prescription digital therapeutics are key to pharma’s future

It's been 20 years since Dolly the sheep. Where's my clone?

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

How Vertex's cystic fibrosis drug is changing patients' lives

Ukraine and a new approach to mental health in war

Biotech lab space demand falls sharply

focus

leisure time

knowledge

hotspot